Using both DNA and RNA, CDx can detect most driver alterations (EGFR, ALK, ROS1, MET, KRAS, BRAF, RET) that are amenable to molecular‐targeted therapy in lung cancer. The gene discussed is EGFR; the disease is lung cancer.